Skip to content
Buy This GLP
← Research
Evidence

Why Couldn’t People Get a GLP-1? A 2023 U.S. Access Survey

In a December 2023 U.S. survey, 49.9% of people who tried to obtain GLP-1 medication reported being unable to get it.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team8 min read
US adults, December 2023, self-reportedhad heard of them81.6%used one (eligible)13.4%tried and failed to get one49.9%The last bar is the one this desk exists for.

A nationwide U.S. cohort asked adults about GLP-1 access in December 2023 (n = 4,555) [1]. Our guide to GLP-1 coverage by indication explains what to look for in a current plan. This survey recorded people’s experience at one point in time.

What did people report?

Among respondents who tried to obtain medication, 49.9% reported that they did not get it. In the subgroup meeting the study’s weight-loss eligibility criteria (n = 1,883), those reporting healthcare access barriers had lower use (adjusted prevalence ratio 0.47, 95% CI 0.35–0.63) [1]. The survey did not determine the reason for each failed attempt.

What can I check for my situation?

A clinician can explain whether there is a prescribing option for your situation. If you get a quote, compare the advertised price with the billed amount for the exact product and supply. Your current options may differ from what survey participants reported in 2023.

Frequently asked

Did the survey explain each unsuccessful attempt?
It recorded reported access, eligibility and barriers. It could not determine why each person was unable to obtain treatment.

Sources

  1. [1] Sanborn J, Fleary SA, Nash D, Penrose K, Parcesepe AM, Piltch-Loeb R (2026). GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort Annals of Epidemiology. PMID 42349695

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence